Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03753204 · ClinicalTrials.gov registry record · Phase 1
Salt-Sensitivity and Immunity Cell Activation
A Phase 1 study of Inflammation and High Blood Pressure, sponsored by Vanderbilt University Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03753204 is a Phase 1 study of Inflammation and High Blood Pressure that is active but no longer recruiting, run by Vanderbilt University Medical Center. The registered enrollment target is 20 participants, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03753204, a Phase 1 study of Inflammation and High Blood Pressure, is active but no longer recruiting, sponsored by Vanderbilt University Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, renal injury, and cardiovascular disease remains unclear. Our data indicated that monocytes exhibit salt sensitivity, and the investigators hypothesize that of salt sensitivity of these and similar immune cells correlate with the hypertensive response to salt intake. Currently, the research tools for diagnosing salt-sensitivity are costly, time consuming and laborious. In this study the investigators will identify monocyte salt-sensitivity as a marker of salt-sensitive hypertension.
Conditions Studied
Interventions
- DRUG Furosemide 40 mg
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03753204
The ClinicalTrials.gov registry entry for NCT03753204 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 288-participant average among 132 other Inflammation trials with a reported enrollment target (93% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Inflammation appearing as the primary indexed condition, and to 1 intervention - of which Furosemide 40 mg is the first listed.
NCT03753204 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT03753204 about?
NCT03753204 is a clinical study titled "Salt-Sensitivity and Immunity Cell Activation". Salt-sensitive hypertension affects nearly 50% of the hypertensive and 25% of the normotensive population, and strong evidence indicates that reducing salt intake decreases blood pressure and cardiovascular events. The precise mechanisms of how dietary salt contributes to blood pressure elevation, r...
What is the current status of trial NCT03753204?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-09-01. Estimated completion is 2026-09-15.
What conditions does trial NCT03753204 study?
This clinical trial studies the following conditions: Inflammation, High Blood Pressure, Salt; Excess.
What interventions are being tested in trial NCT03753204?
The interventions under investigation include: Furosemide 40 mg (DRUG).
Who is sponsoring clinical trial NCT03753204?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03753204 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel Approaches for Improving Vascular Function in Veterans With HFpEF
RECRUITING · Phase 1
-
Safety, Tolerability, and Distribution of Laquinimod Eye Drops : The LION Study
RECRUITING · Phase 1
-
Effects of Etravirine on Endothelial Function in HIV-uninfected Adults: A Pilot Study
COMPLETED · Phase 1
-
Flaxseed Modulates Inflammation and Oxidative Stress in CF
COMPLETED · Phase 1
-
Effect of Statin Therapy on C-reactive Protein Levels in Patients With Chronic Obstructive Lung Disease (COPD)
COMPLETED · Phase 1
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.